Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.


Phase N/A Results


The analysis took into account all 212 randomized patients and showed no statistically significant difference between the enoxaprin and UFH groups. The absolute difference in event rates was 11.3% (p=0.127, Fisher’s exact test, twotailed) in favor of the enoxaparin group. Seventeen percent of the UFH group, compared to 8.5% of the enoxaprin group had adverse treatment-related events. Bleeding complications were experienced by 2.8% (3/106) of patients in the enoxaparin group and 1.9% (2/106) of patients in the UFH group.